A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-541468 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects
Latest Information Update: 20 Oct 2020
At a glance
- Drugs Daridorexant (Primary) ; Rosuvastatin
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 07 Dec 2017 Status changed from recruiting to completed.